Why Is United Therapeutics (UTHR) Up 9% Since Last Earnings Report?

Core Viewpoint - United Therapeutics has seen a 9% increase in share price over the past month, outperforming the S&P 500, but estimates have trended downward recently, raising questions about future performance leading up to the next earnings report [1][2]. Group 1: Earnings Performance - The last earnings report for United Therapeutics was about a month ago, and the stock has performed positively since then [1]. - The stock has a Zacks Rank of 3 (Hold), indicating an expectation of in-line returns in the coming months [4]. Group 2: Estimates and Scores - Estimates for United Therapeutics have been revised downward over the past month, suggesting a cautious outlook [2][4]. - The company has a Growth Score of B, a Momentum Score of F, and a Value Score of B, resulting in an aggregate VGM Score of B, placing it in the second quintile for investment strategy [3].